Delivra Health Brands Past Earnings Performance
Past criteria checks 0/6
Delivra Health Brands has been growing earnings at an average annual rate of 45.2%, while the Pharmaceuticals industry saw earnings growing at 0.03% annually. Revenues have been growing at an average rate of 12.8% per year.
Key information
45.2%
Earnings growth rate
48.6%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 12.8% |
Return on equity | -19.9% |
Net Margin | -5.8% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Delivra Health Brands makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 12 | -1 | 5 | 0 |
31 Dec 23 | 11 | -1 | 5 | 0 |
30 Sep 23 | 12 | 0 | 5 | 0 |
30 Jun 23 | 10 | 0 | 5 | 0 |
31 Mar 23 | 8 | -2 | 5 | 0 |
31 Dec 22 | 8 | -3 | 5 | 0 |
30 Sep 22 | 8 | -6 | 6 | 0 |
30 Jun 22 | 8 | -7 | 6 | 0 |
31 Mar 22 | 8 | -12 | 8 | 0 |
31 Dec 21 | 8 | -12 | 8 | 0 |
30 Sep 21 | 8 | -21 | 8 | 0 |
30 Jun 21 | 8 | -23 | 9 | 0 |
31 Mar 21 | 8 | -24 | 8 | 0 |
31 Dec 20 | 8 | -54 | 11 | 0 |
30 Sep 20 | 8 | -55 | 11 | 0 |
30 Jun 20 | 8 | -57 | 14 | 0 |
31 Mar 20 | 3 | -60 | 17 | 0 |
31 Dec 19 | 4 | -34 | 19 | 0 |
30 Sep 19 | 6 | -26 | 20 | 0 |
30 Jun 19 | 6 | -26 | 20 | 0 |
31 Mar 19 | 9 | -19 | 17 | 0 |
31 Dec 18 | 6 | -17 | 15 | 0 |
30 Sep 18 | 2 | -17 | 13 | 0 |
30 Jun 18 | 1 | -13 | 10 | 0 |
31 Mar 18 | 0 | -13 | 9 | 0 |
31 Dec 17 | 0 | -12 | 8 | 0 |
30 Sep 17 | 0 | -10 | 6 | 0 |
30 Jun 17 | 0 | -8 | 5 | 0 |
31 Mar 17 | 0 | -4 | 3 | 0 |
31 Dec 16 | 0 | -3 | 2 | 0 |
30 Sep 16 | 0 | -3 | 2 | 0 |
30 Jun 16 | 0 | -3 | 2 | 0 |
Quality Earnings: DHBU.F is currently unprofitable.
Growing Profit Margin: DHBU.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DHBU.F is unprofitable, but has reduced losses over the past 5 years at a rate of 45.2% per year.
Accelerating Growth: Unable to compare DHBU.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DHBU.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: DHBU.F has a negative Return on Equity (-19.9%), as it is currently unprofitable.